Celldex Therapeutics, Inc. (CLDX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $31.27: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 7.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality.
Celldex Therapeutics develops antibodies targeting mast cell biology for severe inflammatory and allergic diseases, with no product revenue and an accumulated deficit of $1.8 billion at December 31, 2025. The pipeline centers on barzolvolimab, a KIT antibody in Phase 3 CSU... Read more
Sell if holding. Engine safety override at $31.27: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 7.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.80, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Celldex Therapeutics, Inc.
About Celldex Therapeutics, Inc.
Barzolvolimab, Celldex Therapeutics' lead KIT-targeting antibody, drives the company's entire near-term pipeline as it entered two Phase 3 trials in chronic spontaneous urticaria (CSU) in July 2024, with enrollment completing in February 2026 and 1,939 patients enrolled across 43 countries and more than 500 sites. Celldex had $518.6 million in cash and marketable securities at December 31, 2025, having incurred an operating loss of $287.4 million in 2025 against zero product revenue.
Celldex funds operations entirely through equity and debt financings, licensing fees, and grants, with no approved products. The company spent $111.8 million on clinical trials and $47.1 million on contract manufacturing in 2025, up from $73.0 million and $16.4 million respectively in 2024. Barzolvolimab is under investigation across four indications: CSU (Phase 3, topline Q4 2026), chronic inducible urticaria including cold urticaria and symptomatic dermographism (Phase 3, initiated December 2025), prurigo nodularis (Phase 2, topline expected summer 2026), and atopic dermatitis (Phase 2, topline expected late 2026). CDX-622, a bispecific antibody targeting TSLP and SCF, completed single ascending dose testing with positive data presented in October 2025 and initiated a Phase 1 proof-of-mechanism asthma study in January 2026. Manufacturing is delegated to contract manufacturers with no proprietary production infrastructure. A contingent milestone payment of $52.5 million would become payable to former Kolltan stockholders upon FDA or EMA approval of certain candidates, payable in cash or stock at Celldex's election.
Show full overview
The entire company valuation depends on a single binary readout: the two EMBARQ-CSU Phase 3 studies, with topline data expected Q4 2026. Phase 2 CSU data showed a statistically significant mean UAS7 change of -23.87 for the 300 mg Q8W arm versus -10.47 for placebo at Week 12, and 71% complete response (UAS7=0) in the 150 mg Q4W arm at Week 52. If either Phase 3 study fails to replicate that efficacy, Celldex would face significant capital constraints given a $287.4 million annual operating loss rate, $1.8 billion accumulated deficit, and no revenue-generating product to offset spending.
See also: Healthcare · Biotechnology
From Celldex Therapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-14Recent Developments — Celldex Therapeutics, Inc.
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $42 Price Target — benzinga Jun 15, 2026 positive
- NEWS Reported Sunday, Celldex Presents Phase 1 CDX-622 Data At EAACI 2026 Showing Bispecific Antibody Targeting Soluble SCF A — benzinga Jun 15, 2026 positive
- NEWS Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioede — benzinga Jun 15, 2026 positive
- NEWS Celldex To Highlight Three Presentations From Barzolvolimab And CDX-622 Programs At EAACI Annual Congress 2026 — benzinga Jun 10, 2026 positive
- NEWS UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45 — benzinga Jun 10, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $31.27: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 7.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $29.08. Score 5.3/10, moderate confidence.
Take-profit target: $51.78 (+65.6% upside). Prior stop was $29.08. Stop-loss: $29.08.
Quality below floor (1.4 < 4.0).
Celldex Therapeutics, Inc. trades at a P/E of N/A (forward -6.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover CLDX with a consensus score of 4.2/5. Average price target: $58.
What does Celldex Therapeutics, Inc. do?Celldex Therapeutics develops antibodies targeting mast cell biology for severe inflammatory and allergic diseases,...
Celldex Therapeutics develops antibodies targeting mast cell biology for severe inflammatory and allergic diseases, with no product revenue and an accumulated deficit of $1.8 billion at December 31, 2025. The pipeline centers on barzolvolimab, a KIT antibody in Phase 3 CSU trials with topline data expected Q4 2026, funded by $518.6 million in cash.